Inmune Bio, Inc. Operating Income Loss

• Inmune Bio, Inc. showed a decrease of -11.1% in Operating Income Loss from 2024 to 2025.
• This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Inmune Bio, Inc.'s Operating Income Loss has declined by 4,727.7%.
• Historical annual values: Fiscal year 2025: -$47.38 million | Fiscal year 2024: -$42.64 million | Fiscal year 2023: -$29.74 million | Fiscal year 2022: -$25.95 million | Fiscal year 2021: -$29.15 million | Fiscal year 2020: -$12.23 million | Fiscal year 2019: -$7.76 million | Fiscal year 2018: -$12.44 million | Fiscal year 2017: -$981.5 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026